HKSE:01541 (China)
Â
Ordinary Shares - Class H
HK$
15.10
(+1.07%)
Apr 26
Business Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc
ISIN : CNE100006624
Share Class Description:
HKSE:01541: Ordinary Shares - Class HCompare
Compare
Traded in other countries / regions
01541.Hong Kong IPO Date
2023-09-05Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.14 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.2 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.09 | |||||
| 9-Day RSI | 52.55 | |||||
| 14-Day RSI | 47.14 | |||||
| 6-1 Month Momentum % | -45.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.92 | |||||
| Quick Ratio | 5.92 | |||||
| Cash Ratio | 5.25 | |||||
| Days Sales Outstanding | 34.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -101216.59 | |||||
| Net Margin % | -98351.9 | |||||
| FCF Margin % | -74837.68 | |||||
| ROE % | -51.89 | |||||
| ROA % | -46.22 | |||||
| ROIC % | -151.59 | |||||
| ROC (Joel Greenblatt) % | -267.45 | |||||
| ROCE % | -51.06 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 15100 | |||||
| PB Ratio | 6.89 | |||||
| Price-to-Tangible-Book | 6.89 | |||||
| EV-to-EBIT | -12.13 | |||||
| EV-to-EBITDA | -12.5 | |||||
| EV-to-Revenue | 11878.66 | |||||
| EV-to-FCF | -15.09 | |||||
| Price-to-Net-Current-Asset-Value | 9.21 | |||||
| Price-to-Net-Cash | 10.71 | |||||
| Earnings Yield (Greenblatt) % | -8.24 | |||||
| FCF Yield % | -5.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 0.422 | ||
| EPS (TTM) (HK$) | -1.149 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 47.14 | ||
| 14-Day ATR (HK$) | 1.614723 | ||
| 20-Day SMA (HK$) | 14.762 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (HK$) | 13.58 - 32.15 | ||
| Shares Outstanding (Mil) | 374.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Frequently Asked Questions
What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc(HKSE:01541)'s stock price today?
The current price of HKSE:01541 is HK$15.10. The 52 week high of HKSE:01541 is HK$32.15 and 52 week low is HK$13.58.
When is next earnings date of ImmuneOnco Biopharmaceuticals (Shanghai) Inc(HKSE:01541)?
The next earnings date of ImmuneOnco Biopharmaceuticals (Shanghai) Inc(HKSE:01541) is .
Does ImmuneOnco Biopharmaceuticals (Shanghai) Inc(HKSE:01541) pay dividends? If so, how much?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc(HKSE:01541) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers